Literature DB >> 18765087

Hypertension and hepatic steatosis.

Matthew J Brookes1, Tariq H Iqbal, Brian T Cooper.   

Abstract

Hepatic steatosis (fatty liver) is increasingly recognized as a major component of the metabolic (insulin resistance) syndrome. It can progress to cirrhosis and hepatocellular carcinoma, leading to liver-related mortality. Increasing evidence shows a significant association between hepatic steatosis and hypertension; both are linked to the metabolic syndrome. This review discusses the evidence to support this association, and reviews the diagnosis and management of hepatic steatosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765087     DOI: 10.1007/s11906-008-0035-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  50 in total

1.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.

Authors:  Keith D Lindor; Kris V Kowdley; E Jenny Heathcote; M Edwyn Harrison; Roberta Jorgensen; Paul Angulo; James F Lymp; Lawrence Burgart; Patrick Colin
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

Review 2.  Benefits of lifestyle modification in NAFLD.

Authors:  Stephen A Harrison; Christopher Paul Day
Journal:  Gut       Date:  2007-10-02       Impact factor: 23.059

Review 3.  Hypertension and fatty liver: guilty by association?

Authors:  M J Brookes; B T Cooper
Journal:  J Hum Hypertens       Date:  2007-02-01       Impact factor: 3.012

4.  Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study.

Authors:  Saverio Stranges; Maurizio Trevisan; Joan M Dorn; Jacek Dmochowski; Richard P Donahue
Journal:  Hypertension       Date:  2005-10-03       Impact factor: 10.190

5.  Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis.

Authors:  E Albano; E Mottaran; M Vidali; E Reale; S Saksena; G Occhino; A D Burt; C P Day
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

6.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

7.  Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.

Authors:  Kevin B Barker; Nicole A Palekar; Steven P Bowers; Joel E Goldberg; Joseph P Pulcini; Stephen A Harrison
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

8.  Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients.

Authors:  Paulo S Ribeiro; Helena Cortez-Pinto; Susana Solá; Rui E Castro; Rita M Ramalho; Amélia Baptista; Miguel C Moura; Maria E Camilo; Cecília M P Rodrigues
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

9.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

10.  Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions.

Authors:  Ajay Duseja; Ashim Das; Radha Krishan Dhiman; Yogesh Kumar Chawla; Kiran T Thumburu; Sanjay Bhadada; Anil Bhansali
Journal:  Ann Hepatol       Date:  2007 Oct-Dec       Impact factor: 2.400

View more
  2 in total

1.  Angiotensin receptor blockade recovers hepatic UCP2 expression and aconitase and SDH activities and ameliorates hepatic oxidative damage in insulin resistant rats.

Authors:  Priscilla Montez; José Pablo Vázquez-Medina; Rubén Rodríguez; Max A Thorwald; José A Viscarra; Lisa Lam; Janos Peti-Peterdi; Daisuke Nakano; Akira Nishiyama; Rudy M Ortiz
Journal:  Endocrinology       Date:  2012-10-18       Impact factor: 4.736

2.  Association of adiponectin with hepatic steatosis: a study of 1,349 subjects in a random population sample.

Authors:  Marion Flechtner-Mors; Samuel N George; Suemeyra Oeztuerk; Mark M Haenle; Wolfgang Koenig; Armin Imhof; Bernhard O Boehm; Tilmann Graeter; Richard A Mason; Wolfgang Kratzer; Atilla S Akinli
Journal:  BMC Res Notes       Date:  2014-04-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.